Graft-versus-host disease: teaching old drugs new tricks at less cost

Frontiers in Immunology

Immunology

Shernan G. Holtan¹  Shatha Farhan² 

[1] Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United States;Stem Cell Transplant and Cellular Therapy, Henry Ford Health, Detroit, MI, United States;

关键词: graft-versus-host disease;    drug repurposing;    post-transplant cyclophosphamide;    bortezomib;    human chorionic gonadotropin;    sitagliptin;    a-1-antitrypsin;   

DOI  :  10.3389/fimmu.2023.1225748

 received in 2023-05-19, accepted in 2023-07-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (SCT). Currently, more patients can receive SCT. This is attributed to the use of reduced intensity regimens and the use of different GVHD prophylaxis that breaks the barrier of human leukocyte antigen, allowing an increase in the donor pool. Once an area with relatively few clinical trial options, there has been an increase in interest in GVHD prophylaxis and treatment, which has led to many US Food and Drug Administration (FDA) approvals. Although there is considerable excitement over novel therapies, many patients may not have access to them due to geographical or other resource constraints. In this review article, we summarize the latest evidence on how we can continue to repurpose drugs for GVHD prophylaxis and treatment. Drugs covered by our review include those that have been FDA approved for other uses for at least 15 years (since 2008); thus, they are likely to have generic equivalents available now or in the near future.

【 授权许可】

Unknown   
Copyright © 2023 Farhan and Holtan